Could a diabetes medication be the next wonder drug?

New study uncovers why sotagliflozin may lower risk of heart attack and stroke

2:30 PM

Author | Noah Fromson

A pill bottle is open and pills are placed onto a hand
Getty Images

For millions living with type 2 diabetes, heart disease remains one of the greatest threats to their health. 

Researchers at Michigan Medicine have uncovered a mechanism that may explain why sotagliflozin, an FDA-approved diabetes medication marketed as Inpefa, reduces the risk of heart attack and stroke. In a series of laboratory experiments, the research team found that the drug helps prevent excessive platelet activation, a process that can lead to dangerous blood clots that block flow to the heart and brain. 

The findings, published in the Journal of Clinical Investigation, provide new insight into cardiovascular benefits of the drug that extend beyond blood sugar control.

“A drug that can both decrease the risk for diabetes along with the risk for having a heart attack or stroke could be a turning point in our ability to safely treat this growing population in the US and abroad,” said Michael A. Holinstat, Ph.D., M.S., co-senior author and Professor of Pharmacology, Internal Medicine, and Surgery at University of Michigan Medical School.

Sotagliflozin and heart attack, stroke risk

Sotagliflozin belongs to a class of medications known as sodium-glucose cotransporter (SGLT) inhibitors, which lower blood sugar by blocking the proteins responsible for glucose reabsorption. Unlike the widely used SGLT2 inhibitors, which primary act in the kidneys, sotagliflozin, targets both SGLT2 proteins in the kidneys and SGLT1 proteins in other organs.

Over the past decade, SGLT2 inhibitors such as empagliflozin (Jardiance) and dapagliflozin (Farxiga), have become a mainstay of type 2 diabetes treatment. Over 20% of patients are taking the medications. 

Sotagliflozin has demonstrated an unusual ability in clinical trials. Unlike medications that only target SGLT2, the drug reduced the risk of ischemic events such as heart attack and stroke.

To better understand why, researchers conducted a head-to-head comparison between sotagliflozin and the empagliflozin, or Jardiance. While sotagliflozin limited platelet activation in blood samples from both healthy volunteers and people with type 2 diabetes, empagliflozin had little to no effect.

The team also found that sotagliflozin made platelets less likely to stick together and form blood clots. In mice with injured blood vessels, the drug reduced clot formation by approximately 60%, compared with just 5-10% in animals treated with empagliflozin. 

“These experiments showed that sotagliflozin has a unique effect, and blocking SGLT2 alone is not enough to inhibit platelet aggregation,” said Eugene Chen, M.D., Ph.D., co-senior author and Frederick G. L. Huetwell Professor of Cardiovascular Medicine at U-M Medical School. 

“Sotagliflozin may offer additional protection against blood clots, potentially lowering the risk of heart attack and stroke.”

What makes sotagliflozin different?

Researchers then asked whether SGLT1 inhibition alone could explain the drug’s anti-clotting effect.

Removing SGLT1 from platelets in mice reduced blood clot formation by about 40%. However, removing it genetically or blocking it with a SGLT1-selective inhibitor drug called mizagliflozin did not fully reproduce the effects of sotagliflozin. 

This suggests that sotagliflozin may help prevent blood clots through additional mechanisms beyond blocking SGLT1 in platelets.

They also believe SGLT1 in endothelial cells, which line blood vessels, may influence platelet interactions and clot formation, a possibility that warrants further study.

“Sotagliflozin appears to be in the sweet spot because compounds that have higher levels of SGLT1-selective inhibitors can cause gastrointestinal issues,” said Bertram Pitt, M.D., co-author and Professor Emeritus of Internal Medicine at U-M Medical School.

“We think this could be a wonder drug with potential to offer benefit for many conditions.”

Sotagliflozin is approved for treatment in adults with heart failure, as well as those with type 2 diabetes, chronic kidney disease and other cardiovascular risk factors.

Researchers say in future studies of the drug, they would also like to evaluate the effects on patients with other conditions, such as chronic kidney disease and atrial fibrillation.

“The search for medications that reduce the risk of life-threatening blood clots without increasing the risk of bleeding has continued for decades,” Holinstat said.

“Sotagliflozin has now been demonstrated to serve both functions and may represent the next advancement in prevention of blood clots, heart failure and stroke in patients with and without diabetes.” 

Holinstat and Chen are both members of the Caswell Diabetes Institute.

Paper Cited: “SGLT1/2 inhibitor sotagliflozin, but not SGLT2-selective inhibitor empagliflozin, attenuates platelet activation and thrombosis,” Journal of Clinical Investigation. DOI: 10.1172/JCI201899

Additional authors: Livia Stanger, Ph.D., Krista Goerger, Xu Zhang, M.D., Ph.D., Pooja Yalavarthi, Andrew Rickenberg, Adriana Yamaguchi, Ph.D., Mariane Flores Nascimento, Ph.D., Ashleigh Kilgore, Heeseo Kim, PharmD, Xiaokang Wu, M.D., Ph.D., Yanhong Guo, M.D., Ph.D., Anna R. Dahlgren, Ph.D., Jifeng Zhang, Ph.D., Jordan A. Shavit, M.D., Ph.D., all of University of Michigan.

Funding/disclosures: This work was supported by the National Heart, Lung, and Blood Institute (F31HL179940, R35HL150784, R01HL109946), the National Institute of General Medical Sciences (T32GM140223), and the National Center for Advancing Translational Sciences (T32TR004371) of National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH

The work was also supported by the American Heart Association and Lexicon Pharmaceuticals.

Michael Holinstat is a consultant and receives research funding from Lexicon Pharmaceuticals. Bertram Pitt is a consultant for Lexicon Pharmaceuticals. The remaining authors declare no conflicts of interest.


More Articles About:

Diabetes type 2 diabetes Diabetes Management Heart Failure Heart disease Cardiovascular: Diagnostics & Procedures Cardiovascular: Diseases & Conditions Cardiovascular: Treatment & Surgery Frankel Cardiovascular Center
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

In This Story

Michael Holinstat

Michael A Holinstat

Professor

Yuqing Chen headshot

Yuqing E Chen

Professor

profile-bertram-pitt-2012

Bertram Pitt

Professor Emeritus/a

Related

News Release

New insights into the effect of aging on cardiovascular disease

Aging adults are more likely to have – and die from – cardiovascular disease than their younger counterparts. New basic science research finds reason to link biological aging to the development of narrowed, hardened arteries, independent of other risk factors like high cholesterol.
Sierra works with a device in the lab
Health Lab

Sierra’s Michigan Answer: Researching bold breakthroughs for diabetes

Imagine two patients. Both the same age and height. The same gender and race. Both have a similar medical history. Two people, almost identical in every way. So, why does one of them, seemingly at random, develop diabetes?

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Child in blue shirt smiles on the green grass of a football field
Health Lab

FDA approved drug slows type 1 diabetes progression in 5-year-old patient

After a family history of type 1 diabetes led to early screening through TrialNet, 5-year-old Trevor became Michigan's youngest patient to receive delay-inducing drug TZIELD.
Closeup of newborn baby, whose head is held by a blue medical gloved hand. Blue gloved hand also holds a stethoscope to baby's chest.
Health Lab

More babies with hypoplastic left heart syndrome surviving critical period between surgeries

Collaborative effort helped sustain improvements in survival for babies born with hypoplastic left heart syndrome (HLHS), a serious congenital heart condition that requires multiple surgeries.
A smartphone displaying a red heart with a white EKG line on its screen, set against a teal background.
Health Lab

Mobile health app improves heart failure medication use, dosing after hospitalization

A U-M-led trial found a mobile app improved use and dosing of recommended heart failure medications during the 90 days following a hospital discharge.
Boy in white t-shirt, just chin showing, with hands holding a stethoscope on his chest.
Health Lab

Distance, insurance, social factors may hinder access to lifesaving heart monitoring for children

New research suggests that social, economic and geographic factors may influence whether patients who undergo the Fontan surgery for complex congenital heart disease receive the recommended lifelong cardiac monitoring.
Michael Powers pictured here holding a fish he caught as he stands in a boat. He struggled with pancreatitis for several decades and found answers at University of Michigan Health.
Health Lab

Patient with rare form of diabetes finds answers in genetic testing, clinical trials

Discover how genetic testing and a groundbreaking clinical trial helped one man overcome rare hyperchylomicronemia, high triglycerides, and pancreatitis.
Research image of rat blood vessels before and after norrin treatment
Health Lab

Treatment with norrin helped maintain healthy blood vessels, preserved vision in diabetic rats

Study reveals norrin treatment prevents vision loss from diabetic retinopathy in early and late stages, paving the way for new therapies.